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Available online 31 August 2018Background: Pharmacologic adherence measures were critical to the interpretation of the tenofovir (TFV)-
disoproxil-fumarate/emtricitabine (TDF/FTC) PrEP trials. These measures are being incorporated into PrEP dem-
onstration projects, but currently-available metrics in plasma, cells, hair or urine involve expensive and time-
intensive mass-spectrometry (MS)-based methods. No point-of-care method to assess PrEP adherence in real-
time has yet been implemented. Antibody-based tests allow for low-cost, easy-to-perform, point-of-care drug
detection. In this study, we developed an antibody-based TFV immunoassay and evaluated its test characteristics
among individuals taking TDF/FTC.
Methods: We synthesized possible immunogens based on TFV's molecular structure, injected rabbits with the
conjugated derivatives, and bled themmonthly for subsequent ELISA-testing for TFV-specific antibodies.We pu-
rified an antibodywith specific TFV binding and created dose–response curves for ELISA-quantification.We then
quantified TFV in urine from human participants not taking TDF/FTC and from individuals taking daily TDF/FTC
300mg/200mg for 7 dayswith a 7-daywashout period using ELISAwith this TFV-specific antibody. ELISA results
were compared with the gold-standard test for TFV detection/quantification using liquid-chromatography-tan-
dem-MS (LC–MS/MS).
Findings: None of the urine samples from 115 participants not taking TDF/FTC showed ELISA- reactivity, indicat-
ing 100% specificity (95% CI 97–100%) of the immunoassay. Among participants taking TDF/FTC, 67 of 70 samples
positive by LC–MS/MS were positive by the ELISA-immunoassay for an estimated diagnostic sensitivity of 96%
(95% CI 88–99%). The precision of the assay was high (coefficient of variationb15%). The rank correlation be-
tween ELISA and LC–MS/MS values in the 70 quantitative urine TFV levels positive by LC–MS/MS across a wide
range of concentrations among participants on TDF/FTC was high (r = 0.96).
Interpretation: Our antibody-based immunoassay for measuring TFV in urine performed well compared to the
gold-standard of LC–MS/MS among individuals taking TDF/FTC. A sensitive and specific immunoassay paves
the way for real-time monitoring/feedback on recent adherence to TFV-based regimens, which should optimize




u (H. Okochi), g











Test characteristicsti@ucsf.edu (P. Bacchetti), wrodrigues@immunalysis.com (W.C. Rodrigues), matthew.spinelli@ucsf.edu
rain), jbaeten@uw.edu (J.M. Baeten), rwamba@uw.edu (N.R. Mugo), kngure@pipsthika.org (K. Ngure),
wang@immunalysis.com (G. Wang), mvincent@immunalysis.com (M. Vincent).
e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Research in context
Evidence before this study
The efficacy of tenofovir disoproxil fumarate (TDF)/emtricitabine
(FTC)-based pre-exposure prophylaxis (PrEP) for the prevention
of HIV acquisition is reliant on adequate adherence. Pharmaco-
logic measures of adherence were critical to the interpretation of
the placebo-controlled PrEP trials and remain important tools in
the interpretation of PrEP effectiveness during global PrEP roll-
out. Although PrEP drug levels can be measured in plasma, dried
blood spots (DBS), peripheral blood mononuclear cells (PBMCs),
urine and hair, all of the assays implemented and scaled to date re-
quire expensive, specialized and time-intensive mass-
spectrometry (MS)-based methods. A point-of-care (POC) metric
to determine PrEP adherence in real time has the potential to
both motivate adherence by providing immediate adherence feed-
back to the patient and trigger adherence-promoting
interventions.
Antibody-based tests (lateral flow immunoassays) are low-cost,
enable drug detection to occur within minutes, and can be per-
formed by non-trained personnel. Urine is a particularly suitable
matrix for POC testing since its collection is noninvasive. To find
other reports of pharmacologic measures used for PrEP monitor-
ing, we searched PubMed and abstracts from the Conference on
Retroviruses and Opportunistic Infections (CROI) since 2009
with the search terms “Pre-exposure prophylaxis”, “PrEP”, “adher-
ence”, “pharmacologic measures” “objective measures”, “point-of-
care”, “spectrometry”, “immunoassay”, “antibody”, “tenofovir”,
measures of adherence using “urine”, “plasma”, “PBMCs”, “hair”,
or “DBS or dried blood spots”. A large number of studies have ex-
amined pharmacologic measures of adherence using
spectrometry-based methods in a number of biomatrices in the
context of PrEP. Several studies have examined liquid chromatog-
raphy/tandemmass spectrometry (LC–MS/MS) basedmethods to
analyze TFV in urine among individuals on TDF/FTC. One recent
study describes the development of an immunoassay for TFV
with testing performed only in blank urine samples spiked with
TFV; no validation of antibody specificity or sensitivity in urine
from patients taking TDF/FTC in this study was performed. No
study prior to this report has developed and characterized the
test performance of a TFV-based immunoassay in real urine sam-
ples across a wide range of concentrations from individuals who
have consumed TDF/FTC daily to achieve steady-state concentra-
tions after dosing and during washout.
Added value of this study
We have developed a highly suitable antibody using rabbit serum
to measure TFV concentrations in urine semi-quantitatively via
an immunoassay with a strong selectivity for TFV, strong inhibi-
tion by added TFV into the antigen–antibody mix, and a dose–
response curve showing a strong inverse relationship. Further-
more, we describe the testing of a TFV immunoassay for the
first time using urine from individuals taking TDF/FTC. Our
antibody-based TFV immunoassay is highly specific (100%), sen-
sitive (96%) and estimates quantitative TFV levels in urine that
correlate strongly with those measured via the gold standard of
LC–MS/MS (r=0.96) amongparticipants on TDF/FTC. The trans-
lation of the plate-based immunoassay to a lateral flow immunoas-
say (LFA) is a well-established process and we have experience in
developing low-cost POC assays.
Implications of all the available evidence
Our study, in the context of existing evidence, provides further ev-
idence that PrEP drug concentrations in a biomatrix measure ad-
herence to TDF/FTC consumption. No true POC metric to assess
adherence to TDF/FTC has been implemented to date, although
antibody-based immunoassays have promise. The antibody-
based TFV immunoassay described here is highly sensitive, spe-
cific and precise, measuring concentrations of TFV in urine that
correlate strongly with those derived from the gold standard of
LC–MS/MS across a wide range of values among individuals tak-
ing TDF/FTC. In the context of PrEP roll-out, a packaged POCmet-
ric using this highly-characterized immunoassay will be useful for
both interpreting and optimizing outcomes. Since TFV-based
antiretrovirals are used for both HIV prevention and treatment, a
POC assay tomeasure TFV adherence in real-time can also benefit
antiretroviral treatment (ART) monitoring. A low-cost POC assay
may help avert virologic failure and drug resistance in patients on
ART between more expensive viral load measurements. This
study has important implications for the incorporation of POC ad-
herence metrics into novel adherence-promoting interventions to
maximize the promise of PrEP and ART during global roll-out.
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The profound utility of assessing antiretroviral (ARV) adherence via
pharmacologic metrics was shown for the first time in the placebo-
controlled pre-exposure prophylaxis (PrEP) trials [1]. PrEP with oral
tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) was demon-
strated to be effective in preventing HIV acquisition among at-risk indi-
viduals who take the drug, but objective measures of adherence were
critical to interpreting the initial trial results [2]. Although PrEP was ef-
fective among men-who-have-sex-with-men (MSM) [3] and men and
women in serodiscordant couples [4], there was no efficacy of oral
PrEP observed in two large trials (FEM-PrEP [5] and VOICE [6]) con-
ducted among young sexually active women in Africa. Measurement
of plasma tenofovir (TFV) levels were key in resolving this discrepancy
in results across trials: in the two trials among women, despite self-
reporting N90% adherence to study product, fewer than 30% of active-
arm participants had detectable TFV levels [5,6], thereby explaining
the lack of efficacy. Furthermore, even in the first PrEP trial (iPrEx),
the efficacy of TDF/FTC rose from 44% to an estimated 92% among
those with detectable blood drug levels [3].
Pharmacologic measures examine drug concentrations in a
biomatrix such as plasma [7], peripheral blood mononuclear cells
(PBMCs) [1], hair [8], or dried blood spots (DBS) [9]. Discordance be-
tween self-reportedmeasures of adherence and pharmacologicmetrics,
even in the PrEP open label studies and demonstration projects, where
adherence was higher than in placebo-controlled trials, has highlighted
the importance of incorporating objective measures of adherence dur-
ing PrEP roll-out. As PrEP enters an exciting phase of global implemen-
tation, assessing adherence via objective metrics will aid in defining the
real-world effectiveness of this important prevention HIV strategy.
Beyond study interpretation, assessing adherence objectively and
providing feedback to patients may improve subsequent adherence
and, ultimately, the effectiveness of PrEP. Real-time monitoring of ad-
herence, accompanied by feedback to patients, has led to improved ad-
herence in a variety of disease states, as evidenced by increases in drug
levels and better outcomes [10,11]. In FEM-PrEP [5] and VOICE [6], ac-
cess to a real-timemetric of PrEP adherence could have revealed low ad-
herence and the potential impact of that early on. Qualitative work to
understand non-adherence in VOICE [6,12] revealed that participants,
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cated by plasma drug level data, felt that real-timemonitoring of adher-
ence and feedback in future trials would be acceptable and improve
adherence [12]. In the open-label extension (OLE) study of iPrEx [13],
results of plasma PrEP drug levels collected at prior visits were shared
with individuals at a later visit. Receiving these results was highly ac-
ceptable [13,14] and, for those who were not adherent, motivating to
improve subsequent adherence [14].
Urine may be a particularly suitable matrix for real-time adherence
monitoring, because urine collection is noninvasive and TFV levels in
urine correlate with TDF adherence [15]. However, the current tech-
niques to measure PrEP or PrEP metabolites in urine [15], as well as
other biological matrices (e.g. plasma [7], PBMCs [1], DBS [9], and hair
[8]) all require expensive liquid chromatography–tandem mass spec-
trometry (LC–MS/MS) or other spectrometry-based machines. More-
over, the techniques to extract drug and assess levels via
spectrometry-basedmethods are laborious and require specialized per-
sonnel. None of these methods, therefore, presently allow for point-of-
care monitoring of ARV adherence.
Antibody-based tests (when packaged into lateral flow immunoas-
says) are low-cost, enable drug detection to occur within minutes, and
can be performed by non-trained personnel [16]. However, no
antibody-based test for PrEP adherence has yet been assessed among
individuals taking TDF/FTC. This paper describes the development of
an antibody-based (immunoassay) for TFV with high specificity, sensi-
tivity, precision and correlation with the gold standard metric of LC–
MS/MS among individuals on TDF/FTC. Since TFV-based regimens
(TDF or tenofovir alafenamide (TAF)) are also the backbone of antiretro-
viral treatment (ART), this immunoassay would have additional utility
in monitoring recent adherence during treatment, where consistent
drug-taking is important to prevent virologic failure and viral resistance.
The packaging of this antibody into a low-cost point-of-care (POC) assay
has the potential to aid both interpretation and optimization of out-
comes during PrEP and ART roll-out worldwide.
2. Methods
2.1. Development of a TFV-specific Antibody for the Immunoassay
For the development of a TFV-specific immunoassay (Fig. 1 illus-
trates a schema of immunoassay development) [17], the UCSF Hair An-
alytical Laboratory (HAL), with expertise in LC/MS–MS and analyzing
ARV concentrations in hair in the context of HIV treatment and preven-
tion [18,19], formed a collaboration with Alere™ Rapid Diagnostics, a
company with expertise in developing POC immunoassays [20,21]. Sci-
entists from the UCSF HAL and Alere™ scrutinized the molecular struc-
ture of TFV to identify unique derivatives with structural distinctionFig. 1. Schema of immunofrom endogenous nucleotides. Of note, small molecules like TFV do
not generally elicit an immune response in animals and typically require
conjugation to a large molecular weight carrier protein for immunoge-
nicity. Therefore, following the multi-step chemical synthesis of the
small molecule TFV derivatives (haptens), which involved attachment
of suitable linkers, each was then conjugated to bovine thyroglobulin
(BTG) to prepare the immunogens. Three rabbits were then immunized
per immunogen. The rabbits were injected with boosters of the immu-
nogens and bledmonthly. The rabbit serawere purified by affinity chro-
matography using a protein G column to obtain the immunoglobulin G
(IgG) fraction. The TFV haptens were also conjugated to horseradish
peroxidase (HRP) to prepare the matched enzyme conjugate required
to generate a signal in the immunoassay. The TFV IgGs were
immobilized on 96-well microtiter plates and screened for specific anti-
body binding activity using enzyme linked immunosorbent assays
(ELISA). The analyte of interest (TFV) is then added to the antibody–
antigen mix to obtain inhibition of signal and create a dose–response
curve. The y-axis value is plotted as the percent of the sample bound
to the antibody divided by themaximal possible binding to the antibody
(%B/B0).
2.2. Methods toMeasure Urine Concentrations of TFV via the Immunoassay
and LC–MS/MS
2.2.1. LC–MS/MS Concentrations
Usingpreviously describedmethods [8], theUCSFHAL, aNational In-
stitute of Allergy and Infectious Diseases (NIAID) Division of AIDS’ Clin-
ical Pharmacology and Quality Assurance Program (CPQA) [22]-
certified laboratory, measured TFV levels in urine via LC–MS/MS. TFV
is separated via reverse-phase high performance chromatography (LC)
and quantified byMS/MS using electrospray positive ionization in mul-
tiple reaction monitoring mode (TFV, 287·9/175·9 (Q1/Q3)). A pre-
specified urine TFV concentration ≥500 ng/mlwas considered a positive
test based on prior LC–MS/MS-based studies of TFV in urine from indi-
viduals taking TDF/FTC [15].
2.2.2. ELISA-immunoassay Concentrations
TFV levels were estimated in urine samples from individuals taking
TDF/FTC or not taking TDF/FTC via the TFV-specific antibody using
ELISA. Working solutions of TFV of known concentrations were pre-
pared. Calibrators or different concentrations of TFV were incubated
on a microtiter plate with the hapten to generate a dose response
curve. An ELISA plate reader extrapolates the concentration of TFV in
the unknown specimen based on the calibration curve. Any detectable
TFV concentration above the limit of detection (≥1000 ng/mL)was con-
sidered a positive test.assay development.
µFig. 2. Dose–response curve for quantification of tenofovir concentrations in urine by
immunoassay. %B/Bo represents the percent of the sample bound to the antibody
divided by the maximal possible binding to the antibody. The dose–response shows a
strong inverse relationship between signal and TFV urinary concentrations with this
antibody.
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the Immunoassay
To assess the performance of the immunoassay, urine samples were
tested from two sources: 1) banked urine samples from healthy human
volunteers not taking TDF/FTC and 2) urine collected prospectively from
healthy volunteers recruited to take TDF/FTC as part of the UCSF Point-
of-Care Urine Monitoring for Adherence (PUMA) study. The PUMA
study recruited a convenience sample of ten healthy, non-pregnant
adult volunteers at UCSF to take TDF/FTC 300/200 mg at the same
time each day for 7 days. TDF/FTC tablets were provided by the study.
Participants collected a urine sample prior to TDF/FTC dosing, took
TDF/FTC at the same time every day for 7 days and recorded times of
drug-taking on a study-provided spreadsheet, then collected urine ap-
proximately every three hours in the first 12 h of washout after the
last dose, and then every 24 h after the last dose for the next 7 days. A
total of 102 timed samples were collected from 10 participants (n =
102) in the PUMA study. The UCSF Committee on Health Research
(CHR) approved the protocol for this study and written informed con-
sent from all participants was obtained.
2.4. Data analysis
2.4.1. Specificity
To determine the specificity of the immunoassay, we screened
banked urine samples at Alere from 115 healthy volunteers not taking
TDF/FTC via ELISA using the TFV-specific antibody. We also screened
32 pre-and post-dosing urine samples by the immunoassay which
were negative by the LC–MS/MS assay from participants in the PUMA
study.
2.4.2. Sensitivity
To examine the sensitivity of the immunoassay, we analyzed urine
samples from the 10 participants taking TDF/FTC in the PUMA study.
Urine samples were split and analyzed by both ELISA and LC–MS/MS
(with the latter serving as the gold standard). Of note, since TFV concen-
trates in urine, and to compare TFV levels with those in the literature
[15],we diluted theurine samples 1:1000prior to analysis. Investigators
performing the assays were blinded to all participant information, in-
cluding dosing, and to the results of the other assay (LC–MS/MS or
ELISA-immunoassay) (i.e., each sample was labeled with a randomly-
generated number).
2.4.3. Precision
The ELISA-immunoassay was challenged using 5 non-blinded urine
specimens from each of the 10 volunteers (n = 50) in the PUMA
study at different portions of the dose–response curve over multiple
runs. Timepoints were chosen to represent a range of values across
the concentration range and data from each individual were analyzed
separately. The percent coefficient of variation (% CV) of the assay was
assessed to determine precision.
2.4.4. Agreement and Correlation of Urine TFV ConcentrationsMeasured via
the Immunoassay with Those Measured Using LC–MS/MS
Split urine specimens from the 10 volunteers who collected urine
after controlled dosing of TDF/FTC in PUMAwere used for this analysis.
Agreement between the quantitative urine TFV levels positive both by
the ELISA-immunoassay and by LC–MS/MS was calculated using
Bland–Altman methods [23] after logarithmic transformation in order
to focus on relative errors, which are likely to bemore clinically relevant
than raw errors. We also calculated the rank correlation, using all the
observations thatwere positive by LC–MS/MS.We separately addressed
sensitivity and specificity by cross-tabulating detectable vs undetect-
able TFV concentrations by the two different assays, with confidence in-
tervals calculated from the binomial distribution. This separate
assessment of undetectable specimens ensured that the correlationand agreement calculations would not be inflated by inclusion of spec-
imens without drug.
2.5. Role of The Funding Source
The National Institutes of Health provided funding for this study but
played no role in the collection, analysis, or interpretation of data.
3. Results
3.1. Development of a TFV-specific Antibody for the Immunoassay
The rabbits were injected with boosters and blood was collected
monthly, with subsequent testing of serum by ELISA. After 5 months
of monthly blood collection, each of the three rabbits injected with
oneof the immunogens developed a polyclonal antibody demonstrating
very specific binding to TFV by ELISA. Inhibition of the signal of the
antibody–antigen mix was demonstrated with the addition of increas-
ing concentrations of TFV to create dose response curves (Fig. 2). The
strong inverse relationship between signal and TFV urine concentra-
tions seen with this antibody demonstrated its suitability for further
testing among individuals on TDF/FTC as a TFV immunoassay.
3.2. Study Participants
The 115 urine samples to determine the specificity of the assay are
from frozen urine stocks from volunteers not taking any concomitant
medications. Of the 10 healthy volunteers enrolled in the PUMA study
who ingested daily oral TDF/FTC, 5were female; nonewere on concom-
itant medications; themedian age was 40 years (range 33–49); and the
race/ethnicity was 60% White, 20% South Asian, 20% East Asian.
3.3. Test Characteristics of the Immunoassay (Fig. 3)
3.3.1. Specificity
None of the urine samples from the 115 healthy volunteers not tak-
ing TDF/FTC showed ELISA reactivitywith the isolated antibody, indicat-
ing 100% specificity (95% confidence interval (CI) 97–100%) of the TFV
immunoassay. Moreover, of the 102 urine samples from the 10 partici-
pants recruited in PUMA, 32 (collected prior to dosing and late in the
washout period) were negative for TFV by LC–MS/MS. All 32 of these
LC–MS/MS-negative samples were also negative by the ELISA immuno-
assay, additionally confirming 100% specificity of the assay. Of note, TFV
resembles adenine, an endogenous nucleotide in the human body, but
Fig. 3. 2 × 2 table of LC–MS/MS vs ELISA immunoassay results from banked negative urine
samples and participants in PUMA study. 115 banked negative samples +102 urine
samples from patients taking TDF/FTC in PUMA study; LC–MS/MS gold standard. TP =
True positive; FP = false positive; FN = false negative; TN = true negative.
Fig. 4. Scatterplot of TFV concentrations in urine measured via ELISA immunoassay vs
LCMS/MS Red line indicates the linear regression line between the two sets of values;
the rank correlation coefficient is 0.96; the median (range) of TFV concentrations in
urine in the 70 samples from the PUMA participants' positive by LC–MS/MS was 12,450
(723–98,100) ng/mL.
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not cross-react with endogenous compounds.
3.3.2. Sensitivity
Of the 102 urine samples collected in the PUMA study, 70 were pos-
itive (as defined by ≥500 ng/ml) for TFV by LC–MS/MS. All but 3 of these
70urine sampleswere also positive by the ELISA-immunoassay, indicat-
ing 96% sensitivity (95% CI 88–99%) of the TFV immunoassay relative to
LC–MS/MS. Of note, all 3 of the specimens that were negative by ELISA
but positive by LC- MS/MS were collected from participants late in the
washout period and demonstrated TFV levels b3200 ng/mL.
3.3.3. Precision
The ELISA-immunoassay was challenged using five non-blinded
specimens from each of the 10 participants in PUMA at different por-
tions of the dose–response curve over multiple runs. The %CV of the
assay for these 50 urine specimens was b15%, demonstrating high
precision.
3.4. Agreement and Correlation of Urine TFV Concentrations via the Two
Methods
Split urine specimens from the 10 participants in PUMA were ana-
lyzed for TFV using LC–MS/MS and the ELISA-immunoassay. Natural
log transformed values for the 67 observations positive by both assays
had an average difference of 0.12 (standard deviation (SD) 0.40), corre-
sponding to an average relative difference of 12% and suggesting that
95% of immunoassay values would fall within 51% and 247% of the
LC–MS/MS value [23]. The rank correlation of urine TFV levels by each
assay between all 70 urine TFV levels positive by LC–MS/MS across a
wide range of TFV concentrations was high (r = 0.96)(Fig. 4).
4. Discussion
In this paper, we describe the development an antibody-based assay
to measure TFV in urine quantitatively using ELISA-based methods. The
antibody-based TFV immunoassay described here was highly specific
(100%), sensitive (96%) and estimates TFV levels in urine that correlate
strongly with those measured via LC–MS/MS (r = 0.96) among partici-
pants on TDF/FTC. This antibody-based test, given its excellent perfor-
mance characteristics in clinical samples, paves the way for POC
adherence testing to tenofovir-based regimens.
Although pharmacologic adherence measures of PrEP using the ex-
pensive and labor-intensive modality of LC–MS/MS are available, no
POC method to assess adherence to PrEP has yet been implemented.
This study shows the sensitivity, specificity, precision and correlation
of an antibody-based immunoassay using samples from individuals tak-
ing TDF/FTC for the first time. The next step in the development of a TFV
immunoassaywith these test characteristicswill be to package it into an
easy-to-use, clinically-useful, low-cost tool to characterize adherence
patterns over the past 7 days using interpretative cut-offs for the assay
established by a completed directly-observed therapy (DOT) study ofTDF/FTC [24]. The data from the DOT study of 2, 4 and 7 doses a week
will allow us to determine the appropriate cut-off concentrations of
TFV to create the fully-packaged POC testwith three test lines indicating
no/low, moderate, or high recent adherence, respectively.
The translation of the microplate-based immunoassay (ELISA) to a
lateral flow immunoassay (LFIA) is a well-established process [17].
The LFA components include an adsorbent pad ontowhich the test sam-
ple (e.g. urine) is applied; a conjugate pad where the analyte-specific
antibodies are conjugated to colored particles such as colloidal gold; a
cellulosemembranewhere a test linewill form if the analyte is present;
and a wicking pad designed to draw the sample across the reaction
membrane by capillary action [17]. These components are fixed to an
inert backing material and packaged as a strip test, or within a plastic
casing. Since the lateral flow technology is a mature, commoditized
platform, any current goodmanufacturing practices (cGMP) production
facility should easily be able to support manufacturing for resource-
limited settings. The final price of the LFA (which should be packaged
within the next 6months) is expected to be low (b$2·00/test, for exam-
ple, for point-of-care HIV serologic testing), and its use will be familiar
to health workers already using LFAs to diagnose malaria, HIV, or TB,
as well as clinicians who use the urine toxicology screen to determine
opioid consumption and substance use [25].
A TFV urine-based immunoassay has the potential to monitor and
improve adherence in the context of both HIV prevention and treat-
ment. Since TFV-based regimens (TDF or TAF) are the backbone of anti-
retroviral treatment (ART) for HIV infection worldwide, providing a
low-cost tool to monitor TFV drug-taking behavior at the clinical
point-of-care should also be useful for adherence interpretation during
treatment. Indeed, a low-cost POC assaymay help avert virologic failure
and drug resistance by providingmonitoring between less frequent and
more expensive viral load measurements on ART [26]. Moreover, in
many settings, the return of viral load results from public health labora-
tories requires a substantial turnaround time, thusmaking a POCmetric
particularly valuable. Among HIV-negative individuals on PrEP, in
whom viral loads cannot be measured, pharmacologic measures can
be used to objectively assess adherence. For either PrEP or ART, not
only can real-time feedback on adherence itself improve adherence,
but providing practitioners real-time knowledge on how a patient is ad-
hering to ARVs can allow for interventions to be triggered before pre-
vention or treatment effectiveness is compromised. Finally, the
integration of POC objective adherence metrics into adherence promo-
tion interventions with known efficacy should be evaluated, both for
27M. Gandhi et al. / EClinicalMedicine 2–3 (2018) 22–28interpretation and for real-time modification of the intervention when
ineffective.
4.1. Limitations
Although other immunoassays [27] or aptamer-based assays [28] for
TFV are in development, this is the first study to examine a selective TFV
antibody to measure urine TFV levels among individuals actually taking
TDF/FTC (demonstrating high specificity, sensitivity, precision and cor-
relation with LC–MS/MS across a wide range of urine TFV concentra-
tions), moving this product close to development into a suitable
lateral flow immunoassay. A rapid lateral flow strip test is likely to be
the most cost effective POC test for use in resource-limited settings
[16], and we have experience in developing rapid strip LFAs from suit-
able antibodies, but the POC test still requires packaging andmarketing.
The high specificity of the immunoassay indicates no cross-reactivity of
the antibody with endogenous compounds but, since none of our study
volunteers were on concomitant medications, this study cannot com-
ment on interactionswith other drugs. Finally, while substantial relative
differences occurred between this immunoassay and LC–MS/MSon split
specimens, the ELISA-immunoassay is not meant to replace LC–MS/MS-
based testing, but to allow for the POC testing (which is not yet possible
with LC–MS/MS). The high sensitivity, specificity, and correlation of this
novel assay suggest strong promise for provision of real-time adherence
feedback using the POC immunoassay.
Although urine is a useful, noninvasivematrix for POC testing of ARV
adherence, a major limitation of urine-based assays is that urine levels
reflect plasma levels [29], which measure only short-term adherence
and can be susceptible to temporary increases in adherence prior to
visits (e.g. “white coat adherence”). Despite this theoretical concern,
this phenomenon has been observed only very infrequently in PrEP.
Plasma levels of TFV/FTC served as the “gold standard” adherence met-
ric in all of the placebo-controlled trials of TDF/FTC-based PrEP. Across
these trials, plasma PrEP levels provided robust and critical information
for interpreting trial results. Indeed, our group found no evidence of
white-coat adherence when examining a combination of short and
long-term adherence metrics (hair and plasma levels) in VOICE [30].
To address this limitation, however, a combination of short-and long-
termmetricsmayprovide themost complete detail to examine patterns
of PrEP adherence in roll-out programs [30]. Another way to minimize
this concern in future studies or the clinic is to perform unannounced
urine assays [31]. Individuals with adherence challenges could then be
followed more closely (via differentiated service delivery) by collecting
both additional urine and longer-term PrEP adherence testing (e.g. hair,
DBS), while implementing adherence-promoting interventions. Finally,
self-monitoring of easy-to-perform urine TFV tests, once a protective
threshold is established, may provide immediate feedback and motiva-
tion to patients on PrEP between clinic visits.
5. Conclusion
In conclusion, we have developed and validated an immunoassay to
detect TFV in urine as anobjective adherencemonitoring tool among in-
dividuals taking TDF/FTC. Our antibody-based immunoassay is highly
sensitive, specific and precise, measuring concentrations of TFV in
urine that correlate strongly with those derived from the gold standard
LC–MS/MS-based method among participants on TDF/FTC. Further
work to package this immunoassay into a low-cost POC adherence-
monitoring tool and testing of its potential to improve adherence to
PrEP in at-risk populations is underway. Moreover, we hope that this
workwill spur a new field of investigation on POCmetrics for adherence
to other agents for PrEP (e.g. the dapivirine vaginal ring) or ART. A tool
tomonitor TFV drug-taking behavior at the clinical point-of-care should
improve adherence interpretation and launch an entirely new field of
adherence intervention to maximize the promise of antiretroviral med-
ications for HIV prevention and treatment worldwide.Authors’ Contributions
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